Stay updated on Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.

Latest updates to the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision label updated from v3.5.3 to v3.5.4, indicating a new platform release. This change represents a version upgrade to the ClinicalTrials.gov interface rather than any modification to study content or data.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThis reflects an update to the site/app revision number for the page display (moving from revision v3.5.2 to v3.5.3), with no indication of any content changes to the study record.SummaryDifference0.1%

- Check45 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check74 days agoChange DetectedThe site revision label was updated to v3.5.0 and the previous label v3.4.3 was removed.SummaryDifference0.1%

- Check81 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check88 days agoChange DetectedThe two screenshots show no detectable differences in the page content. Study design, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.1%

Stay in the know with updates to Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.